NCT03718091: M6620 (VX-970) in Selected Solid Tumors

NCT03718091
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ATM, BRCA+, CDK, DNA damage repair mutations, MYC, FBXW7, CCNE1, ARID1A
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express one of the mutations listed
Exclusions: Patients with known, untreated, unstable brain metastases that require treatment – see trial for details; Patients who have previously received treatment with an ATR inhibitor
https://ClinicalTrials.gov/show/NCT03718091

Comments are closed.

Up ↑